Sun Pharmaceutical Industries Inc. history

In support of that effort, Sun moved its administrative offices to Mumbai in 1986.

1987: The company unveils its cardiology products line.

Sun Pharmaceutical added another new product area in 1989 when it began marketing gastroenterology products.

1993: The SPARC research and development facility is opened; offices in Moscow and Toronto are opened.

Sun's manufacturing base grew in 1994 with the opening of a new production plant, in Panoli, supporting its entry into the bulk actives market.

In 1995, United States President Bill Clinton appointed the physicist chairwoman of the United States Nuclear Regulatory Commission, making her the first woman and first African American to hold this prestigious position.

Acquisitions now formed a major part of the company's growth, starting with the purchase of Knoll Pharma's bulk actives manufacturing business based in Ahmednagar in 1996.

Sun opened a second research and development (R&D) facility in 1997, specializing in developing dosage forms and documentation for the fast-growing United States and European generic drugs markets.

In 1998, also, Sun bought Milmet Labs, enabling the company to enter the ophthalmology products market for the first time.

The company completed its acquisition of Gujurat in 1999.

2000: The company acquires the Pradeep Drug company, based in the Madras region.

In the year 2001 the company built a new formulation plant in Dadra.

Sun, which had withdrawn its listing from a number of Indian stock exchanges during 2002, announced a stock split at the end of that year.

In support of these, the company expected to commission a third research and development facility in Baroda in September 2003, while planning began that year for a new product development laboratory, specifically created to support the company's exports to the United States and Europe, in Mumbai.

In the year 2004 the company acquired common stock and options from 2 large shareholders of Caraco increasing stake to over 60% from 44% at a total outlay of about $42 million.

In December 2005 they acquired the intellectual property and assets of Able Labs from the US District Bankruptcy court in New Jersey.

In the year 2007 the company de-merged the innovative research and business into a new company SPARC Ltd.

In June 14 2011 Caraco Pharmaceutical Laboratories Ltd (Caroco) merged with a subsidiary of the company.

Sun Pharma will be eligible to receive development and regulatory milestone payments and additionally sales milestone payments and royalties on net sales. Thus Caraco became a wholly owned subsidiary of the company.In 2012 Sun Pharma bagged USFDA approval for its AND Application for generic Zyprexa.

In 2013 the company announced US FDA approval for generic Cymbalta.

In 2014 the company announced US FDA approval for generic Temodar.

Odomzo (Sonidegib) was approved by the USFDA in July 2015.

The Board of Directors of Sun Pharma at its meeting held on 23 June 2016 approved buyback of fully paid up equity shares of the company through the tender offer route at Rs 900 per share.

CEQUATM will be commercialised in the US in FY20.In July 2018 Sun Pharma announced the USFDA approval for INFUGEMT (gemcitabine in 0.9% sodium chloride injection) for intravenous use in a ready-to-administer (RTA) bag.

Fact Check: The first case of a Corona virus tested positive patient surfaced in Wuhan, China on November 17, 2019.

In the first week of January 2020, roughly 175,000 residents of Wuhan had begun leaving the city to travel to other parts of China to celebrate the upcoming Chinese New Year with their families and loved ones.